Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

FEMY

Femasys Inc

Oct 11 • 01:27PM ET

1.11

Dollar change -0.01
Percentage change -0.89	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: AXSM HOOK HSDT IOVA KALA LBRT MANH ONVO TMDX VRCA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	7.62%	Shs Outstand	21.66M	Perf Week	0.00%
Market Cap	24.68M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	20.54M	Perf Month	-0.89%
Income	-16.69M	PEG	-	EPS next Q	-0.20	Inst Own	7.10%	Short Float	3.19%	Perf Quarter	-0.89%
Sales	0.95M	P/S	25.97	EPS this Y	19.09%	Inst Trans	6.98%	Short Ratio	4.90	Perf Half Y	-14.62%
Book/sh	0.51	P/B	2.19	EPS next Y	38.54%	ROA	-96.51%	Short Interest	0.65M	Perf Year	-32.73%
Cash/sh	0.61	P/C	1.82	EPS next 5Y	-	ROE	-138.37%	52W Range	0.73 - 2.40	Perf YTD	13.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.85%	ROI	-93.88%	52W High	-53.75%	Beta	-2.82
Dividend TTM	-	Quick Ratio	5.93	Sales past 5Y	4.12%	Gross Margin	-32.33%	52W Low	51.23%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	6.47	EPS Y/Y TTM	12.62%	Oper. Margin	-1734.10%	RSI (14)	49.16	Volatility	4.52% 5.56%
Employees	32	Debt/Eq	0.63	Sales Y/Y TTM	-20.57%	Profit Margin	-1756.82%	Recom	1.00	Target Price	8.75
Option/Short	No / Yes	LT Debt/Eq	0.58	EPS Q/Q	4.48%	Payout	-	Rel Volume	0.76	Prev Close	1.12
Sales Surprise	-71.72%	EPS Surprise	-29.23%	Sales Q/Q	-30.90%	Earnings	Aug 08 BMO	Avg Volume	133.70K	Price	1.11
SMA20	-1.14%	SMA50	1.97%	SMA200	-8.97%	Trades		Volume	64,052	Change	-0.89%

Oct-10-24 08:30AM	Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program (GlobeNewswire)
Oct-08-24 08:30AM	Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-02-24 08:30AM	Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed Infertility Treatments (GlobeNewswire)
Sep-18-24 08:30AM	Femasys Announces Infertility Clinic Customers from Coast to Coast (GlobeNewswire)
Sep-11-24 08:30AM	Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed for over $1.3M in Spanish Market (GlobeNewswire) +7.48%
11:53AM	Loading…
Sep-09-24 11:53AM	FDA clears FemChec for fallopian tube occlusion testing (Medical Device Network)
08:30AM	Femasys Inc. Receives U.S. FDA Clearance to Market FemChec , an Innovative Diagnostic Solution for Fallopian Tube Check (GlobeNewswire)
Sep-05-24 08:30AM	Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting (GlobeNewswire)
Sep-03-24 08:30AM	Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.84%
Aug-30-24 06:32AM	Femasys secures CE mark certification for FemVue MINI solution (Medical Device Network)
Aug-29-24 08:30AM	Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution (GlobeNewswire) +10.48%
Aug-27-24 08:30AM	Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters (GlobeNewswire)
Aug-08-24 09:45AM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -18.09%
08:30AM	Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:30AM	Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam (GlobeNewswire) +10.58%
04:32AM	Loading…
Jun-21-24 04:32AM	Femasys gains CE Mark approval for womens health products (Medical Device Network) -9.45%
Jun-20-24 08:30AM	Femasys Receives CE Mark Approval for Four of its Women's Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe (GlobeNewswire) +32.98%
May-17-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative (GlobeNewswire)
May-16-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council (GlobeNewswire)
May-09-24 01:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.63%
09:40AM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update (GlobeNewswire)
May-07-24 08:30AM	Femasys Expands Commercial Management Team with Addition of Experienced New Hires (GlobeNewswire) +5.19%
May-02-24 10:01AM	Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-18-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives (GlobeNewswire)
Mar-28-24 10:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.44% +10.97%
04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:00AM	Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape (GlobeNewswire)
Mar-20-24 08:15AM	Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility (GlobeNewswire) -10.00%
Mar-13-24 09:00AM	Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 (GlobeNewswire) -5.24%
09:00AM	Loading…
Mar-06-24 09:00AM	Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution (GlobeNewswire) -11.27%
Feb-28-24 09:00AM	Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF (GlobeNewswire) +9.26%
Feb-06-24 08:30AM	Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer (GlobeNewswire) +13.27%
Jan-26-24 08:00AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women (GlobeNewswire)
Jan-23-24 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology (GlobeNewswire)
Dec-15-23 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine (GlobeNewswire)
Nov-30-23 08:30AM	Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 05:27PM	30 Countries with the Lowest Median Age in the World (Insider Monkey)
08:30AM	Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch (GlobeNewswire)
Nov-23-23 03:38PM	20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey)
Nov-15-23 08:30AM	PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. (Business Wire) +8.60%
07:30AM	Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech (GlobeNewswire)
Nov-14-23 07:00AM	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update (GlobeNewswire) -10.58%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey) +20.87%
Oct-26-23 08:30AM	Femasys Inc. EU MDR Final Audit Successfully Completed (GlobeNewswire)
Oct-25-23 08:00AM	Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women's Health at the American Association of Gynecologic Laparoscopic Surgeons (GlobeNewswire)
Oct-24-23 04:13AM	Femasys (FEMY) to Report Q3 Earnings: What's in the Cards? (Zacks) +5.98%
Oct-11-23 07:00AM	Femasys Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -6.25%
Oct-04-23 08:30AM	Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine (GlobeNewswire) -8.03%
Oct-03-23 08:30AM	Femasys Inc. MDSAP Surveillance Audit Successfully Completed (GlobeNewswire) -35.99%
Oct-02-23 07:08PM	3 Micro-Cap Stocks Set to Explode Higher (InvestorPlace) +30.54%
Sep-27-23 08:00AM	Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate (GlobeNewswire) -25.00%
Sep-25-23 05:25PM	Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution (GlobeNewswire) +6.97% +346.32%
Sep-20-23 08:30AM	Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control (GlobeNewswire)
Sep-06-23 08:30AM	Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 08:30AM	Femasys Inc. Obtains Medical Device Establishment License from Health Canada (GlobeNewswire)
Aug-10-23 08:00AM	Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire) -6.50%
Aug-03-23 08:45AM	Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc (GlobeNewswire)
Jul-27-23 08:45AM	Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control (GlobeNewswire) +130.77%
Jul-03-23 09:55AM	Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now (Zacks)
Jun-26-23 08:00AM	Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women (GlobeNewswire) +6.25%
Jun-15-23 08:00AM	Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences (GlobeNewswire) +10.87%
Jun-14-23 08:00AM	Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023 (GlobeNewswire) -5.97%
Jun-08-23 08:30AM	Femasys FemCath Intrauterine Catheter Receives Product Approval in Canada (GlobeNewswire) -9.99%
May-11-23 04:05PM	Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023 (GlobeNewswire) -13.15%
08:30AM	Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting (GlobeNewswire)
May-03-23 08:30AM	Femasys FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada (GlobeNewswire)
May-01-23 04:05PM	Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology (GlobeNewswire) +6.09%
Apr-19-23 08:00AM	Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.61%
Apr-18-23 08:00AM	Femasys FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada (GlobeNewswire) +16.67%
Mar-30-23 08:00AM	Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update (GlobeNewswire)
Mar-09-23 08:00AM	Femasys Inc. to Participate in The Post-Roe Fertility Journey Panel Discussion at SXSW 2023 (GlobeNewswire) -8.80%
Dec-19-22 09:00AM	Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device (GlobeNewswire)
Dec-12-22 08:30AM	Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons (GlobeNewswire)
Nov-29-22 07:00AM	Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design (GlobeNewswire) -8.13%
Nov-21-22 08:30AM	Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-12-22 08:17AM	Femasys Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 09:55AM	Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.98%
08:44AM	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire)
Oct-20-22 08:00AM	Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement (GlobeNewswire)
Oct-14-22 04:05PM	Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress (GlobeNewswire)
Oct-12-22 08:00AM	Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs (GlobeNewswire) -16.15%
Oct-06-22 08:01AM	Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control (GlobeNewswire)
Sep-29-22 08:00AM	Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team (GlobeNewswire)
Sep-01-22 04:05PM	Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-10-22 05:45PM	Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.10%
04:05PM	Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update (GlobeNewswire)
Aug-03-22 08:00AM	Femasys To Participate in Upcoming BTIG Biotechnology Conference (GlobeNewswire) +8.81%
Jul-20-22 07:00AM	Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade (GlobeNewswire)
Jul-11-22 08:30AM	Femasys to Participate in the Womens Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET (GlobeNewswire) -6.30%
Jul-06-22 08:00AM	Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board (GlobeNewswire) +5.76%
Jun-28-22 05:31PM	2 Contraceptive Stocks That Could Benefit From Roe v. Wade Reversal (TipRanks) +7.39%
Jun-15-22 08:00AM	Femasys Inc. to Present at the LSX World Congress USA 2022 (GlobeNewswire) -7.14%
May-21-22 10:19AM	Is Femasys (NASDAQ:FEMY) In A Good Position To Invest In Growth? (Simply Wall St.)
May-11-22 04:05PM	Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022 (GlobeNewswire) -7.10%
Mar-25-22 08:00AM	Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference (GlobeNewswire)
Mar-24-22 04:05PM	Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021 (GlobeNewswire)
Feb-24-22 08:00AM	Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer (GlobeNewswire)
Feb-01-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures (PR Newswire)
Jan-31-22 04:24AM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? (Simply Wall St.)

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FEMY

Femasys Inc

Upgrade your FINVIZ experience